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Cultured skin fibroblasts from a proband with a lethal form of osteogenesis
imperfectaproducetwoformsoftypeIcollagenchains,withnormalanddelayedelec-
trophoretic migration; collagen of the proband’s mother was normal. Peptide map-
pingexperimentslocalizedthestructuraldefectintheprobandto1(I)CB8peptidein
which residues123to402arespaned.DirectsequencingofamplifiedcDNAcovering
this region revealed a G to A single base change in one allele of the 1(I) chain, that
converted glycine 388 to arginine. Restriction enzyme digestion of the RT-PCR prod-
uct was consistent with a heterozygous COL1A1 mutation. The novel mutation con-
forms to the linear gradient of clinical severity for the 1(I) chain and results in re-
duced thermal stability by 3C and intracellular retention of abnormal molecules.
Osteogenesis imperfecta (OI) is a dominantly
inheritable disorder of the connective tissue
characterized by brittleness of bone. It is a het-
erogeneous disease with a wide range of clini-
cal phenotypes, from barely detectable to
perinatal lethal. Four OI subtypes are recog-
nized: mild (type I), lethal (type II), severely de-
forming (type III) and moderately severe (type
IV) (Sillence et al., 1979). Almost all forms of
OI are caused by defects in type I collagen
which is the major structural protein of bone,
skin and tendons. The majority of individuals
(>90%) with OI have mutations in the COL1A1
and COL1A2 genes that encode the pro1 and
pro2chainsoftypeIprocollagen,respectively
(Kuivaniemietal.,1991;Prockop,1992).These
mutations include genomic deletions, splicing
mutations causing exon skipping or deletions
of different length. Most of the cases of lethal
OI, however, result from point mutations that
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Abbreviation: OI, osteogenesis imperfecta.produce substitutions for single glycine resi-
dues within the Gly-X-Y repeat units character-
isticofthecollagentriplehelix.Replacementof
a glycine residue with a bulkier amino acid dis-
torts conformation of the triple helix, because
each of the glycine residues is located in the
sterically restricted position in the center of
the triple helix. Mutations that affect quantita-
tively production of type I collagen are respon-
sible for the mildest form of disease (Willing et
al., 1996). On the other hand, point mutations,
splicing mutations, deletions and insertions,
which produce qualitatively abnormal collagen
molecules, have been found to be the cause of
thesevereandlethalformsofOI(Cole,1994).
Inourpreviousstudieswithfibroblastsfrom
a proband with lethal form of OI we have
shown that decreased collagen synthesis and
altered cell growth can be caused by reduced
activityofprolidase,whichmaybeinvolvedin
producing the lethal phenotype (Galicka et al.,
2001). Here, we describe the molecular defect
responsible for the disease. We have identi-
fied a novel Gly388Arg substitution arising
from a mutation in the COL1A1 gene of the
proband occuring in a highly mutagenic CpG
dinucleotide.
MATERIALS AND METHODS
Clinical material. Ultrasonographic exami-
nation at 22 weeks of gestation revealed de-
formed short femurs and poorly ossified skull
of the fetus. The male proband was delivered
and died 3 days later. The clinical and
radiologic picture was characteristic of OI
type II. The proband showed multiple frac-
turesoflongbonesandribs.Theskullwasnot
ossified, membraneous and very soft. He was
fromthefirstpregnancyofapparentlynormal
nonconsanguinous Polish parents, a 24-year-
old mother and 25-year-old father. A second
pregnancy resulted in a normal child.
Biochemical analysis. Skin fibroblast cul-
tures were established from the proband, his
mother and normal control individual as de-
scribed by Bonadio et al. (1985). The biopsies
were obtained with the approval of the Ethics
CommitteeoftheMedicalAcademy(Bia³ystok,
Poland) and with written parental consent.
Confluent fibroblast cultures were labeled
with 50 Ci/ml L-[5-3H]proline (28 Ci/mmol,
Amersham Corp.) for 18 h in fresh Dulbecco’s
modified Eagle medium containing 50 g/ml
of ascorbic acid. Procollagens from the cell
layer and medium were harvested separately
(Bonadio et al., 1985) and converted to col-
lagens by limited proteolysis (4 h at 4C) with
pepsin (50 g/ml). The collagen chains were
separated on 5% SDS/urea/polyacrylamide
gel (Bonadio et al., 1985; Laemmli, 1970)
which was processed for fluorography with
Amplify (Amersham Corp.) as described by
Laskey & Mills (1975). To analyze unglyco-
sylated procollagens, fibroblasts were labeled
as described above, but for 4 h and in the pres-
ence of 0.3 mM ,-dipyridyl.
Cyanogen bromide treatment of proteins in
polyacrylamide gel and separation of peptides
intheseconddimensionby12.5%SDS/PAGE
were performed as described by Bonadio et al.
(1985).
Thermal stability of collagen molecules was
determined as described by Wenstrup et al.
(1991). Briefly, the collagen was incubated at
a range of temperatures from 20 to 43C for
10 min in a Perkin-Elmer thermal cycler, rap-
idly cooled to 20C and then exposed to a mix-
ture of trypsin and chymotrypsin for 2 min.
Digestion products were analyzed electro-
phoretically as described above. Radioactivity
in the protein bands was determined by exci-
sion of the individual bands and scintillation
counting.
Molecular analysis. Total RNA was iso-
lated from cultured skin fibroblasts using the
guanidinium/phenol method (Chomczynski &
Sacchi, 1987). About 1 g of total RNA was
used to synthesize single-stranded cDNA us-
ing RT-PCR (RNA PCR kit, Perkin-Elmer).
For the proband and control, fragments en-
coding the C-half of 1(I) CB8 (aa 261–404)
were amplified by RT-PCR. First-strand syn-
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1836–1865 of the cDNA sequence and a 15
min incubation with MuLV reverse transcrip-
tase at 42C. The forward primer located at nt
1434–1463 of the cDNA sequence was added
for PCR amplification. The conditions of am-
plification were as follows: one cycle of 1 min
at 94C ,3 0sa t6 8 C, and 1 min at 72C, fol-
lowedby35cyclesof30sat94C,30sat68C,
a n d4 5sa t7 2 C. The reaction product was
submitted to agarose gel electrophoresis and
column purification (GenElute Agarose spin
column, Sigma), and then used for asymmet-
ric amplification with the reverse primer in
conditions described above. The PCR product
obtained was directly sequenced with T7
Sequenase (Amersham) using the dideoxy
chain termination method (Sanger et al.,
1977). As sequencing primer a forward
primer (Perkin-Elmer), the 30-mer 5 CCC
AAGGGTCCCGCTGGTGAACGTGGTTCT
3 was used. As an additional control for the
PCR reaction, RNA from control fibroblasts
was also amplified and sequenced as de-
scribed above.
The mutation detected during sequencing of
thecDNAwasconfirmedbydigestingRT-PCR
products containing the mutation site, from
two independent preparations of RNA, with
the restriction endonuclease AvaII. To gener-
ate this product the following primers were
used: the forward primer located at nt
1759–1788 and the reverse located at nt
1836–1865 of the cDNA. The digestion prod-
ucts were separated on a 10% polyacrylamide
gel.
RESULTS
Electrophoretic analysis of collagen
Electrophoretic analysis of type I collagen
synthesized by fibroblasts of the proband
showed in addition to normal collagen chains
the presence of 1(I) and 2(I) chains with de-
layed electrophoretic migration (Fig. 1A). The
abnormal collagen was detected in both me-
dium and cell layer, but in contrast to the con-
trol cells which secreted collagen efficiently,
the OI fibroblasts accumulated it intra-
cellularly. These abnormalities appear to be
specific for type I collagen, since type III colla-
genhadnormalelectrophoreticmigrationand
normalsecretion(Fig.1A). Thissuggeststhat
retention of abnormal collagen is not a gen-
eral secretion problem of the OI fibroblasts.
The collagen molecules of the proband’s
mother were freely secreted into the medium
andmigratedasnormal.Whencollagenofthe
proband was synthesized in the presence of
,-dipyridyl, which blocked lysyl and prolyl
hydroxylation, only normally migrating colla-
gen chains were present (not shown). This
demonstratesthatthedelayedelectrophoretic
mobility resulted from increased
post-translationalmodificationofthecollagen
chains,ratherthantheincreasedlengthofthe
polypeptide.
To obtain an approximate localization of the
mutation along the length of the chain, we de-
termined the gradient of CNBr peptides with
delayed electrophoretic migration. When we
examined the cyanogen bromide peptides,
only the CB8 peptide of the proband 1(I)
chain migrated with a slanted pattern as com-
pared to the mother and control chains
(Fig. 1B). This suggests localization of the mu-
tationintheamino-terminal40%ofthechain.
Localization of mutation
The region of the mRNA encoding the
C-terminal half of the CB8 peptide (aa
261–404) of 1(I) collagen was amplified us-
ing RT-PCR and asymmetric PCR. Direct se-
quencing of the asymmetric PCR product us-
ingtheforwardprimer,fromtwoindependent
RNA preparations, was performed in dupli-
cate. The sequence corresponding to the first
nucleotide of the codon for glycine 388 con-
tained two bands of equal intensity co-mi-
grating in the G and A reaction lanes (Fig. 2).
The GGA codon corresponds to the normal
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results in an arginine substitution for glycine.
The data indicated that the proband was het-
erozygous for codon 388 of the 1(I) pro-
collagen, with one allele coding for glycine
and the other for arginine.
The G-to-A-mutation eliminated a restriction
siteforAvaII.Toconfirmthemutationweam-
plified the region of cDNA containing the mu-
tation site, from the proband and the normal
control. The products were purified and di-
gested with restriction endonuclease AvaII.
Digestion of the control 108 bp PCR product
produced four fragments of 50, 27, 27 and 4
bp, respectively (Fig. 3). When in the proband
the mutation was present, a restriction site
was abolished, and a novel 77 bp band ap-
peared.
Thermal stability of OI collagen
Collagen molecules secreted into the culture
medium of normal and OI cells were submit-
ted to thermal denaturation followed by tryp-
sin-chymotrypsin digestion (Fig. 4). The melt-
ingtemperature(tm)ofcontroltypeIcollagen
chains was 42C, whereas the OI collagen
chains melted at 39C, thus showing that the
triple helix instability resulted from the pres-
enceofabnormalchainsintheheterotrimers.
DISCUSSION
The clinical variability of OI is matched by
extensive heterogeneity in the mutations
causing the disease. Of the over 200 muta-
tions characterized in unrelated individuals,
the majority are substitutions of a charged or
bulky amino-acid residue for the obligatory
glycines in either the gene for pro1(I) or
pro2(I) collagen. Such glycine substitutions
have been associated with a dramatic range of
clinical severity, from barely detectable to
perinatal lethal. However, despite extensive
data, a relationship between the location of
the substitutions for glycine residues and OI
phenotype has proven elusive.
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Figure 1. A. Electropho-
retic mobility of collagen
chains synthesized by der-
mal fibroblasts from the
proband (OI), his mother
(M) and control (C).
Migration positions of the
1(I) and 2(I) chains of type
I collagen and unreduced
1(III) chains of type III col-
lagen are shown. The arrows
indicate the abnormal, slowly
migrating collagen chains.
B. Collagen peptides after
cyanogen bromide diges-
tion.
Gel strips were treated with
CNBr (50 mg/ml) and the
peptides separated by 12.5%
SDS/PAGE. The arrow indi-
cates the CB8 peptide of
proband’s 1(I) with a
slanted migration pattern.Pruchno et al. (1991) postulated that for Gly
to Arg substitutions there is a carboxyl- to
amino-terminal gradient of phenotypic sever-
ity within the 1(I) chain. The most NH2 ter-
minalsubstitutions,G79R(Redford-Badwalet
al., 1996; Gat-Yablonski et al., 1997) and
G85R (Deak et al., 1991), were found in pa-
tientswithmildOItypeI.Thesubstitutionsof
arginineforglycineatposition133resultedin
moderately severe type IV (Ward et al., 2001),
atposition154inmild(Zhuangetal.,1996)or
severe OI (Pruchno et al., 1991) and at posi-
tion 172 in severely deforming type III
(Mackay et al., 1994). Of the lethal mutations
mostNterminalmutationsoccurredat9211R
(Sztrolovics et al., 1994), and all glycine to
arginine substitutions located closer to the
carboxyl-terminal end were found in lethal
cases only. The novel mutation reported here
G388R in a type II OI fetus is consistent with
this gradient of phenotypic severity.
Both the position within the triple helix, and
the nature of the substituting residue deter-
mine phenotypic consequences. Bulkier and
chargedresidues,suchasarginine,havemore
destructive consequences than cysteine or
serine residues, in replacing glycines within
the collagen triple helix. Thus substitution of
glycine 211 with cysteine resulted in milder
OI type III/IV (Wilcox et al., 1994) whereas
Gly211Arg produced lethal OI (Sztrolovics et
al., 1994). Similarly, the substitutions of
glycine 382 with cysteine (Byers, 1990) or
serine(Mackayetal.,1993)resultedinmoder-
ately severe type IV, while arginine produced
lethal type OI (Cohen-Solal et al., 1996). How-
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Figure 2. Direct sequencing of PCR products ob-
tained by asymmetric PCR amplification of 1(I)
cDNA of the proband (OI) and control.
The first band of the codon corresponding to glycine
388 is present as a band of equal intensity in both the G
and A lanes (indicated by the arrows) which identified
the Gly388Arg mutation.
Figure 3. Restriction digestion with AvaII of PCR
products amplified from cDNA of the proband
(OI) and control (C).
Aspredictedbythesequencedata,AvaIIdigestionpro-
duced fragments of 50, 27, and 4 bp from the normal
(N) allele product and fragments of 77, 27 and 4 bp
from the mutant (M) allele product (the 4-bp fragment
wasrunoffthisgel).Thepresenceofcleavageproducts
corresponding to both the normal and mutant allele
products in the proband was consistent with a hetero-
zygousGtoAmutationatnucleotide1815ofCOL1A1.
DpnI digest of pUC18 DNA as a molecular size marker
(St).ever, the phenotypic expression of the disease
may be influenced by other yet unknown fac-
tors, since an identical substitution of
arginine for glycine (G154R) was detected in
three unrelated individuals with different
types OI (Pruchno et al., 1991; Zhuang et al.,
1996). In the reported case we found earlier
that the activity of prolidase, which is essen-
tial in collagen biosynthesis, and expression
of receptors regulating the enzyme activity
weredecreased,whichmaybeinvolvedinpro-
ducing the lethal phenotype (Galicka et al.,
2001). In general, arginine and asparagine
substitutions produced the most drastic con-
sequences on collagen metabolism and stabil-
ity and hence, the phenotypic outcome. How-
ever,whereasallasparticacidsubstitutionsin
pro1(I) seem to be lethal regardless of their
location, the arginine substitutions follow a
severity gradient as illustrated above.
Baker et al. (1989) reported that glycine to
arginine substitutions (G391R and G667R) in
the 1(I) chain were associated with a 1.5C
decrease in stability of collagen. The authors
suggested that the relatively small lowering of
the melting temperature may reflect the na-
ture of the mutations. However, the novel mu-
tation described here, Gly388Arg located
close to the Gly391Arg substitution was asso-
ciated with a 3C decrease of helix stability.
Furthermore, the substitution of arginine for
glycine 85 did not result in fully cooperative
melting of type I collagen as in the above
cases, but in its unfolding in three discrete
segments (Deak et al., 1991). The changed, re-
duced melting temperature could result from
micro-unfolding of a series of independent
“cooperative blocks” as postulated by Wester-
hausenetal.(1990).Thedecreasedstabilityof
the proband’s collagen molecules by 3C sug-
gests its increased susceptibility to degrada-
tion. In combination with impairment of
procollagen synthesis and secretion into me-
dia (Galicka et al., 2001) the amount of type I
collagen available in the extracellular matrix
for fibril formation could be diminished.
As reported for other glycine substitutions,
also in this case a G-to-A transition occurred
at a CpG dinucleotide, which is a common site
of recurrent mutations (Pruchno et al., 1991).
CpG dinucleotides are highly mutagenic be-
cause of the C-to-T transition caused by
methylation and subsequent deamination of
5-methylcytosine. In the COL1A1 gene, only
26 of 338 glycine codons in the triple helix are
susceptible to this mutation mechanism, and
of the 13 sites of recurrent mutations, seven
occur in CpG dinucleotide sequences (Trum-
mer et al., 2001). For COL1A1, apart from
cysteine and serine, arginine is predominant
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Figure 4. Thermal denaturation of
type I collagen from OI (A) and con-
trol (B) fibroblasts.
The thermal denaturation temperature
(tm) was defined as the temperature at
which half of the collagen amount under-
went degradation.in glycine substitutions in the hot spots. The
newly identified glycine to arginine substitu-
tion is, so far, an isolated case which occurred
at position 388 in a CpG dinucleotide site.
It is likely that the novel mutation reported
hereisadenovomutationofonepro(I)allele
as the parents did not show any clinical evi-
dence of OI nor the mother’s protein showed
any molecular defects, although parental
mosaicism (occurring in up to 5–7% of OI pa-
tients) (Zlotogora, 1998) cannot be conclu-
sively ruled out.
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